Molecular Profile Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Profile Name RAD51B wild-type
Gene Variant Detail

RAD51B wild-type (no effect)

Relevant Treatment Approaches


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
RAD51B wild-type ovary serous adenocarcinoma predicted - sensitive Cediranib + Olaparib Clinical Study - Cohort Actionable In a Phase II trial, Cediranib (AZD-2171) and Lynparza (olaparib) treatment was well tolerated, and resulted in an objective response rate (ORR) of 9% (all partial), a 16-week progression-free survival (PFS) of 47%, and a disease control rate (DCR) of 68% in high-grade serous ovarian cancer patients (n=34), and a median PFS of 6.4 months and 1.9 months in patients harboring wild-type (n=9) and reversion mutations (n=5) in either BRCA1, BRCA2, or RAD51B, respectively (PMID: 32444417; NCT02681237). 32444417
RAD51B wild-type breast cancer not applicable N/A Preclinical Emerging SiRNA inhibition of RAD51B in breast cancer cells resulted in increased sensitivity to DNA damaging agents in culture, suggesting that RAD51B could be a promising therapeutic target for sensitization to chemotherapeutic agents in combination therapies (PMID: 25368520). 25368520
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries